Spine surgery company Carlsmed Inc reported on Friday the availability of the aprevo patient-specific spine technology as well as the launch of New Technology Add-On Payment (NTAP) reimbursement across the US spine market.
Effective immediately, the spine fusion procedures utilizing the company aprevo devices are eligible for additional reimbursement from CMS and private payors through the NTAP programme.
The company said its aprevo devices are designed to improve the standard of care for the surgical treatment of patients with adult spinal malalignment. It uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo spine fusion devices to align with the surgeon's goals for each patient.
According to the company, the aprevo devices are US FDA cleared and have been granted US FDA Breakthrough Designation, an industry first for any implanted device and are commercially available in the US.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project